-
公开(公告)号:US20090137547A1
公开(公告)日:2009-05-28
申请号:US12001043
申请日:2007-12-07
申请人: Christoph Steeneck , Christian Gege , Frank Riohter , Holko Kroth , Mouhlee Hochgueriel , Michael Essors , Joshua Van Veldhulzen , Bert Nolte , Brian M. Gallaghor, JR. , Tim Feuerstein , Matthias Schneider , Toralen Arndt , Hongbo Deng , Ralf Blesinger , Xinyuan Wu , Harald Bluhm , Irving Sucholelld , Arthur G. Taverse
发明人: Christoph Steeneck , Christian Gege , Frank Riohter , Holko Kroth , Mouhlee Hochgueriel , Michael Essors , Joshua Van Veldhulzen , Bert Nolte , Brian M. Gallaghor, JR. , Tim Feuerstein , Matthias Schneider , Toralen Arndt , Hongbo Deng , Ralf Blesinger , Xinyuan Wu , Harald Bluhm , Irving Sucholelld , Arthur G. Taverse
IPC分类号: A61K31/5377 , C07D487/04 , A61K31/519
CPC分类号: C07D487/04
摘要: The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
摘要翻译: 本发明一般涉及含酰胺基的药剂,特别涉及含有酰胺的杂双环金属蛋白酶抑制剂化合物。 更具体地,本发明提供了一类新型的杂双环MMP-13抑制和MMP-3抑制化合物,其与当前已知的MMP-13和MMP-3抑制剂相比具有增强的效力。